Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for ZVRA
| Stock Name | Zevra Therapeutics Inc. |
| Ticker | ZVRA(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US4884452065 |
| LEI | 254900CU6T74V18Y1W18 |
Show aggregate ZVRA holdings
News associated with ZVRA
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) saw a large increase in short interest in the month of August. As of August 15th, there was short interest totaling 6,360,000 shares, anincreaseof37.1% from the July 31st total of 4,640,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is currently 5.4 […] - 2025-09-09 02:57:07
- Head to Head Survey: Zevra Therapeutics (NASDAQ:ZVRA) vs. Tourmaline Bio (NASDAQ:TRML)
- Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) and Tourmaline Bio (NASDAQ:TRML – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability. Insider and Institutional Ownership 35.0% of Zevra […] - 2025-08-22 04:38:49
- Zacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to Hold
- Zacks Research downgraded shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) from a strong-buy rating to a hold rating in a research report report published on Monday,Zacks.com reports. Several other equities research analysts also recently issued reports on the stock. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on […] - 2025-08-21 02:58:56
- Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down Following Weak Earnings
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) gapped down prior to trading on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $11.76, but opened at $10.34. Zevra Therapeutics shares last traded at $9.15, with a volume of 1,319,414 shares. The company reported ($0.06) EPS for the quarter, missing the consensus […] - 2025-08-15 02:34:49
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Average PT from Brokerages
- Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) have received an average rating of “Buy” from the nine research firms that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year […] - 2025-08-12 02:30:48
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Up 166.3% in July
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totaling 4,900,000 shares, anincreaseof166.3% from the June 30th total of 1,840,000 shares. Currently,9.1% of the shares of the stock are sold short. Based on an average daily […] - 2025-08-05 02:20:49
- Zevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to Buy at Wall Street Zen
- Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Sunday. Other analysts have also recently issued reports about the stock. Cantor Fitzgerald lifted their target price on shares of Zevra Therapeutics from $25.00 to $29.00 […] - 2025-07-22 02:12:58
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Consensus Price Target from Brokerages
- Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) have been assigned a consensus recommendation of “Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average […] - 2025-07-18 02:22:58
- Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated by Analysts at HC Wainwright
- HC Wainwright initiated coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) in a report published on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $26.00 price target on the stock. A number of other research analysts also recently issued reports on ZVRA. Cantor Fitzgerald restated an “overweight” rating and set […] - 2025-07-03 05:26:58
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Analysts
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) has been given a consensus recommendation of “Buy” by the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […] - 2025-06-20 03:08:48
- 25,075 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by D. E. Shaw & Co. Inc.
- D. E. Shaw & Co. Inc. bought a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,075 shares of the company’s stock, valued at approximately $209,000. […] - 2025-05-29 04:36:54
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.29 Average Price Target from Brokerages
- Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) have been assigned a consensus rating of “Buy” from the nine research firms that are covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […] - 2025-05-29 02:27:25
- Zevra Therapeutics (NASDAQ:ZVRA) Upgraded at Wall Street Zen
- Wall Street Zen upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) from a hold rating to a buy rating in a research report report published on Thursday. ZVRA has been the subject of several other reports. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in […] - 2025-05-23 05:10:54
- Zevra Therapeutics (NASDAQ:ZVRA) Earns Overweight Rating from Cantor Fitzgerald
- Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $25.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 196.56% from the company’s current price. […] - 2025-05-16 03:04:59
- Raymond James Financial Inc. Acquires Shares of 26,916 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
- Raymond James Financial Inc. acquired a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm acquired 26,916 shares of the company’s stock, valued at approximately $224,000. A number of other institutional investors have also modified their holdings of ZVRA. Barclays PLC increased its […] - 2025-05-13 04:20:54
- Barclays PLC Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
- Barclays PLC raised its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) by 402.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 289,688 shares of the company’s stock after purchasing an additional 232,089 shares during the quarter. Barclays PLC owned […] - 2025-05-01 05:12:56
- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $21.57 Consensus Target Price from Brokerages
- Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) have received an average recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price […] - 2025-02-18 04:13:00
- China Universal Asset Management Co. Ltd. Buys Shares of 11,318 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
- China Universal Asset Management Co. Ltd. bought a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 11,318 shares of the company’s stock, valued at approximately $94,000. A number of other […] - 2025-02-04 07:15:12
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ZVRA holdings
| Date | Number of ZVRA Shares Held | Base Market Value of ZVRA Shares | Local Market Value of ZVRA Shares | Change in ZVRA Shares Held | Change in ZVRA Base Value | Current Price per ZVRA Share Held | Previous Price per ZVRA Share Held |
|---|
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ZVRA by Blackrock for IE00BYXG2H39
Show aggregate share trades of ZVRA| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-06 | BUY | 288 | 10.650 | 10.660 | 10.659 | USD 3,070 | 8.74 |
| 2025-10-03 | BUY | 672 | 9.750 | 9.770 | 9.768 | USD 6,564 | 8.73 |
| 2025-10-02 | BUY | 96 | 9.310 | 9.490 | 9.472 | USD 909 | 8.73 |
| 2025-09-30 | BUY | 192 | 9.510 | 9.510 | 9.510 | USD 1,826 | 8.72 |
| 2025-09-26 | BUY | 192 | 9.770 | 9.954 | 9.936 | USD 1,908 | 8.71 |
| 2025-09-25 | BUY | 192 | 9.520 | 9.955 | 9.911 | USD 1,903 | 8.71 |
| 2025-09-18 | BUY | 97 | 7.940 | 8.010 | 8.003 | USD 776 | 8.71 |
| 2025-09-17 | BUY | 294 | 7.330 | 7.550 | 7.528 | USD 2,213 | 8.72 |
| 2025-09-11 | SELL | -97 | 7.950 | 8.070 | 8.058 | USD -782 | 8.75  Profit of 67 on sale |
| 2025-09-10 | BUY | 194 | 7.980 | 8.176 | 8.156 | USD 1,582 | 8.75 |
| 2025-09-05 | SELL | -96 | 8.950 | 8.990 | 8.986 | USD -863 | 8.75  Loss of -22 on sale |
| 2025-08-29 | SELL | -288 | 9.070 | 9.390 | 9.358 | USD -2,695 | 8.75 Loss of -176 on sale |
| 2025-08-27 | BUY | 192 | 9.360 | 9.480 | 9.468 | USD 1,818 | 8.74 |
| 2025-08-26 | SELL | -96 | 9.410 | 9.460 | 9.455 | USD -908 | 8.74 Loss of -69 on sale |
| 2025-08-25 | BUY | 96 | 9.360 | 9.460 | 9.450 | USD 907 | 8.73 |
| 2025-08-20 | SELL | -380 | 9.280 | 9.335 | 9.330 | USD -3,545 | 8.72 Loss of -230 on sale |
| 2025-08-18 | BUY | 190 | 9.200 | 9.445 | 9.420 | USD 1,790 | 8.72 |
| 2025-08-08 | SELL | -188 | 12.020 | 12.220 | 12.200 | USD -2,294 | 8.65 Loss of -667 on sale |
| 2025-08-05 | BUY | 94 | 11.440 | 11.440 | 11.440 | USD 1,075 | 8.59 |
| 2025-08-01 | SELL | -282 | 11.110 | 11.370 | 11.344 | USD -3,199 | 8.55 Loss of -787 on sale |
| 2025-07-30 | BUY | 376 | 10.990 | 11.240 | 11.215 | USD 4,217 | 8.52 |
| 2025-07-17 | SELL | -188 | 12.660 | 12.750 | 12.741 | USD -2,395 | 8.31 Loss of -832 on sale |
| 2025-07-11 | SELL | -760 | 12.530 | 12.550 | 12.548 | USD -9,536 | 8.18 Loss of -3,317 on sale |
| 2025-07-07 | BUY | 285 | 11.270 | 11.500 | 11.477 | USD 3,271 | 8.08 |
| 2025-07-02 | BUY | 5,225 | 9.410 | 9.625 | 9.603 | USD 50,178 | 8.04 |
| 2025-06-25 | BUY | 190 | 9.330 | 9.430 | 9.420 | USD 1,790 | 8.00 |
| 2025-06-11 | BUY | 192 | 9.380 | 9.620 | 9.596 | USD 1,842 | 7.90 |
| 2025-06-10 | BUY | 192 | 9.280 | 9.420 | 9.406 | USD 1,806 | 7.89 |
| 2025-06-04 | SELL | -97 | 8.950 | 9.059 | 9.048 | USD -878 | 7.84 Loss of -117 on sale |
| 2025-04-23 | BUY | 96 | 7.250 | 7.550 | 7.520 | USD 722 | 7.76 |
| 2025-04-10 | SELL | -768 | 6.560 | 6.680 | 6.668 | USD -5,121 | 7.86 Profit of 915 on sale |
| 2025-04-08 | SELL | -96 | 6.590 | 7.400 | 7.319 | USD -703 | 7.89 Profit of 55 on sale |
| 2025-04-07 | SELL | -96 | 7.050 | 7.410 | 7.374 | USD -708 | 7.91 Profit of 51 on sale |
| 2025-04-04 | SELL | -485 | 7.040 | 7.350 | 7.319 | USD -3,550 | 7.92 Profit of 293 on sale |
| 2025-04-01 | BUY | 3,398 | 7.320 | 7.630 | 7.599 | USD 25,821 | 7.94 |
| 2025-03-31 | SELL | -261 | 7.490 | 7.745 | 7.719 | USD -2,015 | 7.94 Profit of 59 on sale |
| 2025-03-14 | SELL | -1,392 | 8.310 | 8.490 | 8.472 | USD -11,793 | 7.92 Loss of -771 on sale |
| 2025-03-07 | SELL | -174 | 8.100 | 8.190 | 8.181 | USD -1,423 | 7.91 Loss of -47 on sale |
| 2025-03-04 | SELL | -88 | 7.390 | 7.435 | 7.430 | USD -654 | 7.92 Profit of 43 on sale |
| 2025-02-25 | BUY | 174 | 7.360 | 7.580 | 7.558 | USD 1,315 | 7.97 |
| 2025-02-19 | SELL | -87 | 7.730 | 7.960 | 7.937 | USD -691 | 8.01 Profit of 6 on sale |
| 2025-02-13 | BUY | 261 | 7.990 | 8.000 | 7.999 | USD 2,088 | 8.01 |
| 2025-02-12 | BUY | 87 | 7.720 | 7.750 | 7.747 | USD 674 | 8.02 |
| 2025-02-11 | BUY | 348 | 7.540 | 7.570 | 7.567 | USD 2,633 | 8.04 |
| 2025-01-17 | BUY | 348 | 8.050 | 8.090 | 8.086 | USD 2,814 | 8.20 |
| 2025-01-16 | BUY | 348 | 7.930 | 8.100 | 8.083 | USD 2,813 | 8.24 |
| 2025-01-10 | SELL | -172 | 8.110 | 8.410 | 8.380 | USD -1,441 | 8.61 Profit of 39 on sale |
| 2025-01-08 | SELL | -348 | 8.530 | 8.720 | 8.701 | USD -3,028 | 8.76 Profit of 21 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ZVRA
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 241,137 | 0 | 851,965 | 28.3% |
| 2025-09-18 | 417,207 | 26,612 | 1,086,897 | 38.4% |
| 2025-09-17 | 402,129 | 0 | 855,559 | 47.0% |
| 2025-09-16 | 821,873 | 0 | 1,297,127 | 63.4% |
| 2025-09-15 | 206,640 | 0 | 567,541 | 36.4% |
| 2025-09-12 | 290,869 | 0 | 866,908 | 33.6% |
| 2025-09-11 | 169,248 | 7,950 | 489,369 | 34.6% |
| 2025-09-10 | 348,389 | 100 | 728,302 | 47.8% |
| 2025-09-09 | 267,050 | 200 | 655,166 | 40.8% |
| 2025-09-08 | 214,947 | 0 | 501,480 | 42.9% |
| 2025-09-05 | 121,386 | 0 | 344,080 | 35.3% |
| 2025-09-04 | 426,712 | 0 | 713,981 | 59.8% |
| 2025-09-03 | 230,767 | 0 | 362,814 | 63.6% |
| 2025-09-02 | 155,293 | 300 | 399,511 | 38.9% |
| 2025-08-29 | 140,021 | 340 | 319,704 | 43.8% |
| 2025-08-28 | 149,028 | 28 | 332,293 | 44.8% |
| 2025-08-27 | 88,926 | 42 | 166,459 | 53.4% |
| 2025-08-26 | 80,224 | 0 | 188,655 | 42.5% |
| 2025-08-25 | 172,285 | 101 | 576,407 | 29.9% |
| 2025-08-22 | 137,975 | 31 | 365,672 | 37.7% |
| 2025-08-21 | 723,028 | 940 | 1,514,065 | 47.8% |
| 2025-08-20 | 129,397 | 22 | 302,833 | 42.7% |
| 2025-08-19 | 235,322 | 400 | 565,442 | 41.6% |
| 2025-08-18 | 161,619 | 0 | 403,480 | 40.1% |
| 2025-08-15 | 556,853 | 449 | 1,088,052 | 51.2% |
| 2025-08-14 | 642,785 | 38,915 | 1,515,106 | 42.4% |
| 2025-08-13 | 974,562 | 90,450 | 3,513,126 | 27.7% |
| 2025-08-12 | 185,789 | 0 | 626,405 | 29.7% |
| 2025-08-11 | 161,615 | 39 | 528,372 | 30.6% |
| 2025-08-08 | 174,678 | 0 | 446,039 | 39.2% |
| 2025-08-07 | 167,681 | 0 | 509,998 | 32.9% |
| 2025-08-06 | 127,618 | 10,244 | 269,134 | 47.4% |
| 2025-08-05 | 82,730 | 0 | 184,276 | 44.9% |
| 2025-08-04 | 107,484 | 0 | 220,230 | 48.8% |
| 2025-08-01 | 212,402 | 0 | 311,069 | 68.3% |
| 2025-07-31 | 173,401 | 0 | 297,102 | 58.4% |
| 2025-07-30 | 135,611 | 0 | 287,945 | 47.1% |
| 2025-07-29 | 79,977 | 0 | 251,195 | 31.8% |
| 2025-07-28 | 162,439 | 0 | 482,280 | 33.7% |
| 2025-07-25 | 99,355 | 248 | 465,749 | 21.3% |
| 2025-07-24 | 71,226 | 6,389 | 272,421 | 26.1% |
| 2025-07-23 | 90,000 | 0 | 423,197 | 21.3% |
| 2025-07-22 | 79,031 | 5 | 257,220 | 30.7% |
| 2025-07-21 | 157,485 | 485 | 454,455 | 34.7% |
| 2025-07-18 | 179,931 | 0 | 427,854 | 42.1% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy